Navigation Links
Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
Date:7/7/2011

DUBLIN, July 7, 2011 /PRNewswire/ --


 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has filed lawsuits in the U.S. District Court for the District of New Jersey against Roxane Laboratories, Inc., ("Roxane"), and in the U.S. District Court for the Central District of California against Watson Laboratories, Inc., ("Watson"), respectively, for infringement of certain of Shire's VYVANSE patents.

The lawsuits were initiated in response to Abbreviated New Drug Applications ("ANDAs") filed by each of Roxane and Watson seeking FDA approval to market and sell generic versions of all currently approved doses of VYVANSE.

Under the Hatch-Waxman Act, the FDA must refrain from approving the Roxane and Watson ANDAs before August 23, 2014, or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier.

Shire will provide details of any additional Paragraph IV certifications received advising of ANDA filings on VYVANSE, and any litigation that is subsequently initiated, in its periodic filings on Forms 10-Q and 10-K.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Investor Relations    
Eric Rojas (erojas@shire.com)    +1-781-482-0999    
Sarah Elton-Farr (seltonfarr@shire.com)    +44-1256-894157

Media    
Jessica Mann (jmann@shire.com)    +44-1256-894-280    
Matthew Cabrey (mcabrey@shire.com)    +1-484-595-8248



'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
2. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
3. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
4. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
5. Reportlinker Adds Shire plc: PharmaVitae Profile
6. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
7. Shire plc - Statement re ProAmatine
8. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
9. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
10. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
11. Shire plc Appoints Two New Board Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2019)... Calif. (PRWEB) , ... October 30, 2019 , ... ... 29, 2019 to showcase the many roles innovation and technology play in educating ... Center for Innovation, featured hands-on learning opportunities and presentations by WesternU administrators and ...
(Date:10/22/2019)... ... October 22, 2019 , ... nQ Medical, Inc. of Cambridge, ... Most Fundable Companies List which was announced at a showcase event yesterday in Los ... annual revenue, strong business plans, and impressive near-term growth projections to be named one ...
(Date:10/17/2019)... ... October 16, 2019 , ... My Gene ... information, has published a new white paper that explores how frequently medical management ... to how patients and medical providers can be kept informed as changes are ...
(Date:10/10/2019)... ... October 10, 2019 , ... VirTrial today ... centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable ... certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT). ...
Breaking Biology Technology:
(Date:11/14/2019)... , ... November 13, 2019 , ... ... Robert Peterson, RAC , a regulatory affairs and program management executive with ... and medical device industries, has joined the firm as an Expert Consultant. ...
(Date:11/14/2019)... , ... November 13, 2019 , ... Personalized Stem ... first patients in an FDA approved clinical trial for stem cell treatment of ... formation of the company as a subsidiary of VetStem Biopharma. , In July of ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... orthopedic medical devices, today announced the creation of a Global Regulatory Affairs Department, ... Medical Device industry is that the regulatory element to any Medtech organization is ...
Breaking Biology News(10 mins):